---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-209437"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T05:56:30.942799+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes

## Summary
- Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.
- Used ~$402.5M cash and 2,168,806 common shares to exchange $399.5M of existing 3.50% notes due 2027.
- Initial conversion price ~$68.42 per share, ~37.5% premium over $49.76 last sale price.
- Remaining proceeds to fund aficamten commercial launch, development, pipeline, and general corporate purposes.
- Notes not redeemable before Oct 6, 2028; convertible under certain stock price and event conditions.

## SEC filing metadata
- accession: 0001193125-25-209437
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/d933506d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-209437
- JSON: https://secwatch.observer/filing/0001193125-25-209437.json
- Plain text: https://secwatch.observer/filing/0001193125-25-209437.txt

## Source-grounded claims
- claim_id: c7e8634a8101251c9b2108d05403ac6d43207daf
  claim: CYTOKINETICS INC incurred convertible notes of $750.0 million aggregate principal amount with initial purchasers at 1.75% per year maturing October 1, 2031.
  evidence_excerpt: On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.